Urgent needs to accelerate the race for COVID-19 therapeutics-Reference-Cited by-同舟云学术

Urgent needs to accelerate the race for COVID-19 therapeutics

Published:2021-06 Issue: Volume:36 Page:100911
ISSN:2589-5370
Container-title:EClinicalMedicine
language:en
Short-container-title:EClinicalMedicine

Author:

Batista Carolina^ORCID,Shoham Shmuel,Ergonul Onder,Hotez Peter,Bottazzi Maria Elena,Figueroa J. Peter,Gilbert Sarah,Gursel Mayda,Hassanain Mazen,Kang Gagandeep,Kaslow David,Kim Jerome H.,Lall Bhavna,Larson Heidi,Naniche Denise,Sheahan Timothy,Wilder-Smith Annelies,Sow Samba O.,Yadav Prashant,Strub-Wourgaft Nathalie

Publisher

Elsevier BV

Subject

General Medicine

Reference10 articles.

1. Medical oxygen crisis: a belated COVID-19 response;Usher;Lancet,2021

2. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial;López-Medina;JAMA,2021

3. A living WHO guideline on drugs for covid-19;Siemieniuk;BJM,2020

4. What happens in Brazil? A pandemic of misinformation that culminates in an endless disease burden;Cardoso;Rev Soc Bras Med Trop,2021

5. WHO. Therapeutics and COVID-19: living guideline. November 20, 2020. https://apps.who.int/iris/bitstream/handle/10665/336729/WHO-2019-nCov-remdesivir-2020.1-eng.pdf?sequence=1&isAllowed=y (accessed December 03, 2020)

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In silico screening and evaluation of antiviral peptides as inhibitors against ORF9b protein of SARS-CoV-2;3 Biotech;2024-08-06

2. Treating COVID-19: Targeting the Host Response, Not the Virus;Life;2023-03-06

3. Mercapto-pyrimidines are reversible covalent inhibitors of the papain-like protease (PLpro) and inhibit SARS-CoV-2 (SCoV-2) replication;RSC Advances;2023

4. Health-Promoting Behaviors among Older Adults with Noncommunicable Diseases in Rural and Urban Areas during the New Normal Post-COVID-19 Era: A Structural Equation Modeling Analysis;Nutrients;2022-12-25

5. Ribavirin aerosol in hospitalized adults with respiratory distress and COVID ‐19: An open‐label trial;Clinical and Translational Science;2022-11-03